CoChat

Characterization of the metastatic phenotype of a panel of established osteosarcoma cells

Open access
Ren, Ling, Mendoza, Arnulfo, Zhu, Jack, Briggs, Joseph W., Halsey, Charles, Hong, Ellen S., Burkett, Sandra S., Morrow, James J., Lizardo, Michael M., Osborne, Tanasa, Li, Samuel Q., Luu, Hue H., Meltzer, Paul, Khanna, Chand · 2015 · Oncotarget
Cited by 119

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Ling Ren 1 , Arnulfo Mendoza 1 , Jack Zhu 2 , Joseph W. Briggs 1 , Charles Halsey 3 , Ellen S. Hong 1 , Sandra S. Burkett 4 , James J. Morrow 5 , Michael M. Lizardo 1 , Tanasa Osborne 6 , Samuel Q. Li 5 , Hue H. Luu 7 , Paul Meltzer 2 and Chand Khanna 1 1 Molecular Oncology Section - Metastasis Biology Group, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA 2 Genetic Branch, National Cancer Institute, Bethesda, Maryland, USA 3 Molecular Pathology Unit, Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland, USA 4 Comparative Molecular Cytogenetics Core Facility, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA 5 School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA 6 National Institute of Environmental Health, Research Triangle Park, North Carolina, USA 7 Department of Orthopedic Surgery & Rehabilitation Medicine, University of Chicago, Medicine & Biological Sciences, Chicago, USA Correspondence to: Chand Khanna, email: // Keywords : osteosarcoma, PHLDA1/TDAG51, tumor metastasis Received : June 08, 2015 Accepted : July 12, 2015 Published : August 13, 2015 Abstract Osteosarcoma (OS) is the most common bone tumor in pediatric patients. Metastasis is a major cause of mortality and morbidity. The rarity of this disease coupled with the challenges of drug development for metastatic cancers have slowed the delivery of improvements in long-term outcomes for these patients. In this study, we collected 18 OS cell lines, confirmed their expression of bone markers and complex karyotypes, and characterized their in vivo tumorgenicity and metastatic potential. Since prior reports included conflicting descriptions of the metastatic and in vivo phenotypes of these models, there was a need for a comparative assessment of metastatic phenotypes using identical procedures in the hands of a single investigative group. We expect that this single characterization will accelerate the study of this metastatic cancer. Using these models we evaluated the expression of six previously reported metastasis-related OS genes. Ezrin was the only gene consistently differentially expressed in all the pairs of high/low metatstatic OS cells. We then used a subtractive gene expression approach of the high and low human metastatic cells to identify novel genes that may be involved in OS metastasis. PHLDA1 (pleckstrin homology-like domain, family A) was identified as one of the genes more highly expressed in the high metastatic compared to low metastatic cells. Knocking down PHLDA1 with siRNA or shRNA resulted in down regulation of the activities of MAPKs (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 mitogen-activated protein kinases (MAPKs). Reducing the expression of PHLDA1 also delayed OS metastasis progression in mouse xenograft models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5177

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 119

Metadata

Authors
Ren, L., Mendoza, A., Zhu, J., Briggs, J. W., Halsey, C., Hong, E. S., Burkett, S. S., Morrow, J. J., Lizardo, M. M., Osborne, T., Li, S. Q., Luu, H. H., Meltzer, P., & Khanna, C.
Venue
Oncotarget
Published
2015-08-13
Volume
6
Issue
30
Pages
29469-29481
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1908149944
Cited by
119
References
8
FWCI
5.95
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.